The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS rucaparib arm.
 
Simon J. Crabb
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; MSD; Roche
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BeiGene; EMD Serono; MSD; Novartis; Pfizer; Roche
Research Funding - Astex Pharmaceuticals; AstraZeneca; Clovis Oncology; Roche
Expert Testimony - Merck/Pfizer; MSD
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Janssen
 
Syed A. Hussain
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck; Pfizer; Pierre Fabre; Roche
Research Funding - Boehringer Ingelheim; Janssen-Cilag; Pierre Fabre
Travel, Accommodations, Expenses - Bayer; Boehringer Ingelheim; Janssen-Cilag; MSD Oncology; Pfizer; Pierre Fabre; Roche
 
Eileen Soulis
No Relationships to Disclose
 
Samantha Hinsley
No Relationships to Disclose
 
Avril Trevethan
No Relationships to Disclose
 
Yee Pei Song
No Relationships to Disclose
 
Jim Barber
No Relationships to Disclose
 
John A. Frew
No Relationships to Disclose
 
Joanna Gale
No Relationships to Disclose
 
Guy Faust
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen; Novartis; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Eisai; Janssen Oncology; Merck Serono; Merck/Pfizer; MSD Oncology; Novartis; Pierre Fabre; Roche; Roche; Sanofi
Travel, Accommodations, Expenses - Bayer; Janssen; Novartis
 
Susannah Joy Brock
No Relationships to Disclose
 
Ursula Brigid McGovern
No Relationships to Disclose
 
Omi Parikh
No Relationships to Disclose
 
Deborah Enting
No Relationships to Disclose
 
Santhanam Sundar
Honoraria - Bayer UK; Clovis Oncology
Consulting or Advisory Role - Roche
Speakers' Bureau - Pfizer
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Roche
 
Gihan Ratnayake
No Relationships to Disclose
 
Kathryn Lees
No Relationships to Disclose
 
Thomas Powles
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche
 
Robert J. Jones
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; EUSA Pharma; Ipsen; Janssen; Merck Serono; MSD Oncology; Novartis; Pfizer; Pharmacyclics; Roche/Genentech; Sanofi; Seagen
Consulting or Advisory Role - Clovis Oncology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); Exelixis (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Ipsen; Janssen; MSD